Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03383575 · ClinicalTrials.gov registry record · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
A Phase 2 study of Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 3
- Study locations
NCT03383575 is a Phase 2 study of Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 63 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (46% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT03383575, a Phase 2 study of Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase II trial studies the side effects and how well azacitidine and enasidenib work in treating patients with IDH2-mutant myelodysplastic syndrome. Azacitidine and enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- DRUG Azacitidine
- DRUG Enasidenib
Study Locations (3)
Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore
Ohio
- Cleveland Clinic Foundation - Cleveland
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2018-01-17 |
| Est. Completion | 2027-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03383575
The ClinicalTrials.gov registry entry for NCT03383575 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (46% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.
NCT03383575 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Maryland, Ohio, Texas.
Frequently Asked Questions
What is clinical trial NCT03383575 about?
NCT03383575 is a clinical study titled "Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome". This phase II trial studies the side effects and how well azacitidine and enasidenib work in treating patients with IDH2-mutant myelodysplastic syndrome. Azacitidine and enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT03383575?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2018-01-17. Estimated completion is 2027-02-28.
What conditions does trial NCT03383575 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent High Risk Myelodysplastic Syndrome, IDH2 Gene Mutation.
What interventions are being tested in trial NCT03383575?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Azacitidine (DRUG), Enasidenib (DRUG).
Who is sponsoring clinical trial NCT03383575?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03383575 being conducted?
This trial has 3 study locations across Maryland, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
RECRUITING · Phase 2
-
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
RECRUITING · Phase 2
-
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.